Gliclazide

Gliclazide is an oral hypoglycaemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®.

Form and Composition:

Each modified-release tablet contains 30 mg of gliclazide.

Indication:

Type 2 diabetes.

Dosage:

30 to 120 mg depending on response, once daily with breakfast, including in elderly patients or those with mild-to-moderate renal failure

Properties:

Hypoglycaemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. glycaemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.

Contraindications:

type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.

Interactions:

Hyperglycaemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, ß-2 agonists. Its hypoglycaemic action may be potentiated by phenylbutazone, alcohol, fluconazole, ß-blockers, possibly ACE inhibitors.

Adverse effects:

Hypoglycaemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).

Overdosage:

Possible severe hypoglycaemia requiring urgent IV glucose and monitoring.

© Medic8 ® All Rights Reserved.